Frequently Asked Questions

Generalized myasthenia gravis (gMG) is an autoimmune disease that damages the communication between your nerves and muscles. It is estimated that over 71,000 people in the United States are living with anti-acetylcholine receptor (AChR) antibody-positive gMG, which is the specific type of gMG that ULTOMIRIS is approved to treat.

Common gMG symptoms include muscle weakness that may lead to trouble with arm or leg strength, talking or chewing, and other basic daily functions. Stress, changes in the weather, and using your muscles throughout the day may trigger gMG symptoms, which can occur at any time and make daily planning difficult.

Everyone’s journey toward their gMG diagnosis is different, but many people report feeling limited by their symptoms, which can impact daily routines and activities. If you think that you might have gMG, you can use the questionnaire below to track your gMG symptoms and start a conversation with your doctor at your next visit.

ULTOMIRIS is indicated for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. If you still feel limited by your gMG symptoms, even after treatment, consult your doctor to see if ULTOMIRIS may be right for you. You can use the questionnaire below to track your gMG symptoms and start a conversation with your doctor at your next visit.

ULTOMIRIS is proven to bind to and block C5, a protein within a part of your immune system called “complement.” Though the exact way that ULTOMIRIS works is unknown in gMG, complement is known to incorrectly attack your muscles and contribute to the gMG symptoms that you may experience.

ULTOMIRIS was studied in a clinical trial (CHAMPION-MG) that included 175 adults with varying degrees of severity of anti-AChR antibody-positive gMG. The trial measured the impact of ULTOMIRIS through improvements in participants’ daily activities and muscle weakness. Over 90% of people in the trial had mild or moderate gMG, and most were taking an immunosuppressive therapy when they first started taking ULTOMIRIS.

In a clinical trial, ULTOMIRIS was proven to reduce the impact of gMG symptoms on activities of daily living. ULTOMIRIS was also proven to reduce muscle weakness, improving physical functions such as seeing, talking, and swallowing.

ULTOMIRIS is given via intravenous infusion by a healthcare professional at an infusion center or doctor's office. Starting 2 weeks after your initial dose, ULTOMIRIS offers predictable maintenance dosing just once every 8 weeks. If you have not already had them, you must receive vaccines for meningococcal infection at least 2 weeks before your first dose of ULTOMIRIS. Your healthcare provider or nurse will make sure you receive these vaccines at least 2 weeks before your first infusion.

Side effects were studied in the ULTOMIRIS clinical trial (CHAMPION-MG). The most common side effects reported in ≥10% of people receiving ULTOMIRIS were diarrhea and upper respiratory tract infection. In the trial, only 2 people taking ULTOMIRIS stopped treatment due to side effects compared to 3 people taking placebo.

There are currently no available data on the use of ULTOMIRIS in pregnant women or on the presence of ULTOMIRIS in human milk. If you are pregnant, you should consult with your doctor before receiving ULTOMIRIS. Breastfeeding should be discontinued during treatment with ULTOMIRIS and for 8 months after the final dose.

If you are on ULTOMIRIS, you can take advantage of OneSource™, a free, personalized patient support program offered by Alexion. Get help with insurance coverage, answers to questions about your treatment with ULTOMIRIS, access to community resources, and more.

Getting started on ULTOMIRIS is simple with 3 easy steps . Learn how to connect with a doctor and prepare for what you may expect while on ULTOMIRIS.

Alexion is committed to helping you afford ULTOMIRIS. While your out-of-pocket cost for ULTOMIRIS may vary, Alexion’s OneSource patient support program can provide help with navigating insurance matters and eligibility for financial assistance.

Alexion hosts webinars and events for people with gMG so that they have the opportunity to hear from leading doctors and to learn from other people receiving ULTOMIRIS.

ULTOMIRIS is built on the foundation of SOLIRIS. Both treatments bind to and block complement protein C5, but ULTOMIRIS is designed to last longer so that you only need a maintenance dose once every 8 weeks, starting 2 weeks after your initial dose.

Talk to your doctor about making the transition to ULTOMIRIS. Transitioning from SOLIRIS to ULTOMIRIS should be done at the discretion of your doctor, who will use their clinical judgment in deciding the appropriate course of action.